内镜黏膜下剥离术(ESD)治疗T1b期食管癌的结局:一项回顾性研究
这项回顾性研究纳入2016年12月至2023年4月接受ESD且病理分期为T1b期食管癌的患者16例(共17处病灶),中位随访28个月。ESD整块切除率100%、R0切除率82.3%,无即时围术期并发症;结论认为ESD在T1b期食管癌中安全且整块和R0切除率高,复发率低但需密切监测,需更大规模研究确定长期临床疗效。
要点
- 16例患者共17处病理T1b期食管癌灶,中位随访28个月(范围3-75)。
- ESD整块切除率100%、R0切除率82.3%,16/17例(94.1%)当日出院,无即时围术期并发症。
- 4/17处(23.5%)为治愈性切除且无肿瘤复发;非治愈性切除13例中,仅ESD组5例中2例(40%)复发。
核心结论
- ESD在T1b期食管癌中安全,整块切除率和R0切除率高;复发率低但患者需要密切监测。
- 需要更大规模的研究来确定ESD在T1b期食管癌中的长期临床疗效。
研究设计与样本
- 回顾性研究,纳入2016年12月至2023年4月接受ESD且病理分期为T1b期食管癌的患者。
- 共16例患者、17处病理T1b期食管癌灶,中位随访28个月(范围3-75个月)。
- 分析患者人口学资料、肿瘤特征和ESD技术结局,随访确定无病生存率和肿瘤复发率。
主要发现
- ESD整块切除率100%,R0切除率82.3%。
- 16/17例患者(94.1%)当日出院,无即时围术期并发症。
- 4/17处(23.5%)为治愈性ESD切除,无肿瘤复发。
- 非治愈性切除13例中,仅ESD组5例中2例(40%)出现肿瘤复发;ESD+手术组1例死于手术并发症,5例中1例(20%)随访时肿瘤复发;ESD+放化疗组无肿瘤复发。
局限性
- 原文结论指出需要更大规模的研究来确定ESD在T1b期食管癌中的长期临床疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The role of submucosal endoscopic dissection (ESD) in management of invasive esophageal cancer (EC) remains unclear. In this case series, we evaluate the clinical and technical outcomes of patients who underwent ESD with pathologically staged T1b EC. METHODS: This retrospective study included patients who underwent ESD between December 2016 and April 2023 with pathologically staged T1b EC. Patient demographics, tumor characteristics, and ESD technical outcomes were analyzed. Patients were followed to determine disease-free survival and tumor recurrence rates. RESULTS: Sixteen patients with a total of 17 pathologically staged T1b ECs were included in this case series with a median follow-up time of 28 months [range 3-75]. ESD had high en-bloc (100%) and R0 (82.3%) resection rates. 16/17 patients (94.1%) were discharged the same day, and there were no immediate perioperative complications. 4/17 patients (23.5%) had curative ESD resections with no tumor recurrence. Among those with non-curative resections (n = 13), 5 patients had ESD only, 6 had ESD + surgery, and 2 underwent ESD + chemoradiation. In the ESD only group, 2/5 patients (40%) had tumor recurrence. In the ESD + surgery group, one patient died from a surgical complication, and 1/5 (20%) had tumor recurrence at follow-up. There was no tumor recurrence among patients who had ESD + chemoradiation. CONCLUSION: ESD is safe with high en-bloc and R0 resection rates in T1b EC. Recurrence rates are low but patients need close monitoring. Larger-scale studies are needed to determine the long-term clinical efficacy of ESD in T1b EC.
引用
- Youssef M, Hanna C, Motomura D, et al. Endoscopic submucosal dissection (ESD) outcomes in T1B esophageal cancer: a retrospective study. Surg Endosc. 2024. PMID: 38594364. doi:10.1007/s00464-024-10824-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。